In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: TG Therapeutics trades 41.6% above its PERT-weighted fair value of $31.63, indicating potential overvaluation despite excellent financial health scores. The negative DCF valuation contrasts sharply with high P/E targets, reflecting divergent outlooks on future cash flows. Zero downside risk in Monte Carlo analysis suggests limited immediate price decline scenarios amid valuation uncertainty.